{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:21:40Z","timestamp":1789554100922,"version":"build-2803163510"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cefiderocol is a novel \u03b2-lactam with activity against carbapenem-resistant Acinetobacter baumannii (CRAB), but its role in CRAB pulmonary infections is controversial due to limited evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the association between cefiderocol-containing regimens treatment and 28-day mortality in carbapenem-resistant A. baumannii ventilator-associated pneumonia (VAP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An observational cohort study including critically ill COVID-19 patients with CRAB-VAP admitted to two ICUs of a large academic hospital in Rome between September 2020 and December 2022. The primary outcome was 28-day all-cause mortality. A propensity score was created to balance the cefiderocol- and non-cefiderocol-containing groups. A propensity-weighted multiple logistic regression model was calculated to evaluate risk factors for 28-day mortality. Survival curves were calculated using the Kaplan\u2013Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>121 patients were enrolled, 55 were treated with cefiderocol- and 66 with non-cefiderocol-containing regimens. The 28-day all-cause mortality was 56% (68\/121). A statistically significant difference in 28-day mortality was found between cefiderocol- and non-cefiderocol- containing regimens groups (44% versus 67%, P\u200a=\u200a0.011). In the propensity-adjusted multiple logistic regression, cefiderocol (OR 0.35 95% CI 0.14, 0.83) was a predictor of 28-day survival, Charlson comorbidity index (OR 1.36 95% CI 1.16, 1.78), SOFA score (OR 1.24 95% CI 1.09, 1.57) and septic shock (OR 3.71 95% CI 1.44, 12.73) were all associated with increased 28-day mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cefiderocol-containing regimens were associated with reduced 28-day mortality in CRAB-VAP. The sample size and the observational design limit the study\u2019s conclusions. Future RCTs are needed to establish cefiderocol\u2019s definite role in these infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlad085","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T09:47:27Z","timestamp":1688032047000},"source":"Crossref","is-referenced-by-count":38,"title":["Cefiderocol-containing regimens for the treatment of carbapenem-resistant\n                    <i>A. baumannii<\/i>\n                    ventilator-associated pneumonia: a propensity-weighted cohort study"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6573-9584","authenticated-orcid":false,"given":"Emanuele","family":"Rando","sequence":"first","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica\u2014Sezione di Malattie Infettive, Universit\u00e0 Cattolica del Sacro Cuore , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore Lucio","family":"Cutuli","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienza dell'Emergenza, Anestesiologiche e della Rianimazione, Fondazione Policlinico Universitario A Gemelli IRCCS , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Sangiorgi","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica\u2014Sezione di Malattie Infettive, Universit\u00e0 Cattolica del Sacro Cuore , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa Sofia","family":"Tanzarella","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienza dell'Emergenza, Anestesiologiche e della Rianimazione, Fondazione Policlinico Universitario A Gemelli IRCCS , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Giovannenze","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A Gemelli IRCCS , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"De Angelis","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A Gemelli IRCCS , Rome , Italy"},{"name":"Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Universit\u00e0 Cattolica del Sacro Cuore , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Murri","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica\u2014Sezione di Malattie Infettive, Universit\u00e0 Cattolica del Sacro Cuore , Rome , Italy"},{"name":"Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A Gemelli IRCCS , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Antonelli","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienza dell'Emergenza, Anestesiologiche e della Rianimazione, Fondazione Policlinico Universitario A Gemelli IRCCS , Rome , Italy"},{"name":"Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Universit\u00e0 Cattolica del Sacro Cuore , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Fantoni","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica\u2014Sezione di Malattie Infettive, Universit\u00e0 Cattolica del Sacro Cuore , Rome , Italy"},{"name":"Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A Gemelli IRCCS , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"De Pascale","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienza dell'Emergenza, Anestesiologiche e della Rianimazione, Fondazione Policlinico Universitario A Gemelli IRCCS , Rome , Italy"},{"name":"Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Universit\u00e0 Cattolica del Sacro Cuore , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"2023072020381253500_dlad085-B1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European economic area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2023072020381253500_dlad085-B2","doi-asserted-by":"crossref","DOI":"10.15620\/cdc:82532","volume-title":"Antibiotic Resistance Threats in the United States, 2019","author":"Centers for Disease Control and Prevention (U.S.)","year":"2019"},{"key":"2023072020381253500_dlad085-B3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2023072020381253500_dlad085-B4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1378\/chest.08-1116","article-title":"Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant Gram-negative bacteria","volume":"134","author":"Kollef","year":"2008","journal-title":"Chest"},{"key":"2023072020381253500_dlad085-B5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jinf.2019.05.017","article-title":"Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: clinical features, therapy and outcome from a multicenter study","volume":"79","author":"Russo","year":"2019","journal-title":"J Infect"},{"key":"2023072020381253500_dlad085-B6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13756-022-01113-y","article-title":"Microbiologically confirmed infections and antibiotic-resistance in a national surveillance study of hospitalised patients who died with COVID-19, Italy 2020\u20132021","volume":"11","author":"Floridia","year":"2022","journal-title":"Antimicrob Resist Infect Control"},{"key":"2023072020381253500_dlad085-B7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3390\/antibiotics10050545","article-title":"Ventilator-associated pneumonia in patients with COVID-19: a systematic review and meta-analysis","volume":"10","author":"Ippolito","year":"2021","journal-title":"Antibiotics"},{"key":"2023072020381253500_dlad085-B8","doi-asserted-by":"crossref","first-page":"S544","DOI":"10.1093\/cid\/ciz827","article-title":"In vitro activity of cefiderocol against a broad range of clinically important Gram-negative bacteria","volume":"69","author":"Yamano","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023072020381253500_dlad085-B9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2023072020381253500_dlad085-B10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/antibiotics11010003","article-title":"Cefiderocol for severe carbapenem-resistant A. baumannii pneumonia: towards the comprehension of its place in therapy","volume":"11","author":"Rando","year":"2021","journal-title":"Antibiotics"},{"key":"2023072020381253500_dlad085-B11","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/cid\/ciaa1410","article-title":"Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023072020381253500_dlad085-B12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jgar.2020.09.019","article-title":"Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii","volume":"23","author":"Oliva","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2023072020381253500_dlad085-B13","first-page":"746","article-title":"Cefiderocol efficacy in a real-life setting: single-centre retrospective study","volume":"12","author":"Palermo","year":"2023","journal-title":"Antibiot Basel Switz"},{"key":"2023072020381253500_dlad085-B14","doi-asserted-by":"crossref","first-page":"e02142-21","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023072020381253500_dlad085-B15","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious diseases society of America guidance on the treatment of AmpC \u03b2-lactamase\u2013producing enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023072020381253500_dlad085-B16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2023072020381253500_dlad085-B17","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/SHK.0b013e3181cc0418","article-title":"Predictors of mortality in adult patients with ventilator-associated pneumonia: a meta-analysis","volume":"33","author":"Siempos","year":"2010","journal-title":"Shock"},{"key":"2023072020381253500_dlad085-B18","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023072020381253500_dlad085-B19","volume-title":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines","author":"COVID-19 Treatment Guidelines Panel","year":"2021"},{"key":"2023072020381253500_dlad085-B20","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"2023072020381253500_dlad085-B21","doi-asserted-by":"crossref","first-page":"e00695-21","DOI":"10.1128\/Spectrum.00695-21","article-title":"Diagnosis and treatment of bacterial pneumonia in critically ill patients with COVID-19 using a multiplex PCR assay: a large Italian hospital\u2019s five-month experience","volume":"9","author":"Posteraro","year":"2021","journal-title":"Microbiol Spectr"},{"key":"2023072020381253500_dlad085-B22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3390\/antibiotics12010125","article-title":"Use of high-dose nebulized colistimethate in patients with colistin-only susceptible Acinetobacter baumannii VAP: clinical, pharmacokinetic and microbiome features","volume":"12","author":"De Pascale","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2023072020381253500_dlad085-B23","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/jac\/dkac080","article-title":"Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing","volume":"77","author":"Matuschek","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2023072020381253500_dlad085-B24"},{"key":"2023072020381253500_dlad085-B25","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ajic.2019.03.003","article-title":"Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis","volume":"47","author":"Du","year":"2019","journal-title":"Am J Infect Control"},{"key":"2023072020381253500_dlad085-B26","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40265-021-01580-4","article-title":"Cefiderocol: a review in serious Gram-negative bacterial infections","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"2023072020381253500_dlad085-B27","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1093\/jac\/dkz123","article-title":"Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects","volume":"74","author":"Katsube","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023072020381253500_dlad085-B28","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/14787210.2022.2020099","article-title":"All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies","volume":"20","author":"Lodise","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2023072020381253500_dlad085-B29","doi-asserted-by":"crossref","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","article-title":"Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study","volume":"3","author":"Pascale","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2023072020381253500_dlad085-B30","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3390\/antibiotics11060723","article-title":"Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics"},{"key":"2023072020381253500_dlad085-B31","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(21)00194-8","article-title":"Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens","volume":"21","author":"Choby","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2023072020381253500_dlad085-B32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1378\/chest.122.1.262","article-title":"Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia","volume":"122","author":"Iregui","year":"2002","journal-title":"Chest"},{"key":"2023072020381253500_dlad085-B33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13054-020-03013-2","article-title":"The challenge of ventilator-associated pneumonia diagnosis in COVID-19 patients","volume":"24","author":"Fran\u00e7ois","year":"2020","journal-title":"Crit Care Lond Engl"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/5\/4\/dlad085\/50918888\/dlad085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/5\/4\/dlad085\/50918888\/dlad085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T17:01:19Z","timestamp":1689872479000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlad085\/7227125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlad085","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,7,11]]},"article-number":"dlad085"}}